NCT06319950View on ClinicalTrials.gov

High-dose Furmonertinib Versus Osimertinib in Advanced EGFRm NSCLC Patients With Brain Metastases

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

255

Participants

Timeline

Start Date

April 1, 2024

Primary Completion Date

December 30, 2026

Study Completion Date

December 30, 2026

Conditions
Lung Cancer, Nonsmall Cell
Interventions
DRUG

Furmonertinib

Furmonertinib, 160mg po qd

DRUG

Osimertinib

Osimertinib，80mg po qd

All Listed Sponsors
lead

Taizhou Hospital

OTHER

NCT06319950 - High-dose Furmonertinib Versus Osimertinib in Advanced EGFRm NSCLC Patients With Brain Metastases | Biotech Hunter | Biotech Hunter